# Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

> **NCT00635089** · PHASE3 · COMPLETED · sponsor: **Ception Therapeutics** · enrollment: 190 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** reslizumab

## Key facts

- **NCT ID:** NCT00635089
- **Lead sponsor:** Ception Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2017-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635089, "Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00635089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*